阿帕替尼治疗晚期难治性软组织肉瘤28例的疗效和安全性  

Efficacy and Safety of Apatinib in the Treatment of 28 Patients with Advanced Refractory Soft Tissue Sarcomas

作　　者：吕汪霞[1] 袁梅琴[1] 史钟[1] 赵亚珍[1] 杨云山[1] 钟海均[1] LYU Wang-xia;YUAN Mei-qin;SHI Zhong(Zhejiang Cancer Hospital,Hangzhou 310022,China)

机构地区：[1]浙江省肿瘤医院

出　　处：《肿瘤学杂志》2018年第6期592-596,共5页Journal of Chinese Oncology

摘　　要：[目的]评价阿帕替尼治疗晚期难治性软组织肉瘤疗效及不良反应。[方法]2015年5月至2017年5月晚期难治性软组织肉瘤28例患者口服阿帕替尼500mg,每日1次,28d为1个疗程,直至疾病进展或无法耐受的毒副反应。采用RECISIT1.1评价疗效,CTCAE4.03评价不良反应。[结果]28例患者中,PR 6例（21.4%）,SD 17例（60.7%）,PD 5例（17.9%）,ORR为24.1%,DCR为82.1%。患者的中位生存期为3.7个月（95%CI：2.9-4.4）,中位总生存期为9.1个月（95%CI：7.3-11.0）。3-4级不良反应较多的血液学毒性为白细胞减少和中性粒细胞减少,发生率均为10.7%,非血液学毒性为手足综合征（14.2%）、高血压（7.1%）和蛋白尿（7.1%）。[结论]阿帕替尼治疗晚期难治性软组织肉瘤体现出一定的疗效,且不良反应可耐受。[Objective] To evaluate the efficacy and safety of apatinib in patients with advanced refractory soft tissue sarcomas. [Methods] Between May 2015 to May 2017,twenty-eight patients were enrolled. Patients received apatinib500 mg once daily in a 28-day cycle. Response was assessed using RECIST 1.1 criteria. Toxicity was recorded using CTCAE version 4.03. [Results]Of 28 patients,6 patient had PR（21.4%）,17 patients had SD（60.7%） and 5 had PD（17.9%）. The ORR was 24.1% and DCR was 82.1%. The median PFS was 3.7 months（95%CI：2.9-4.4）. T he median OS was 9.1 months（95%CI：7.3-11.0）. The grade3/4 toxicities were leukopenia（10.7%）,neutropenia（10.7%）,hand-foot syndrome（14.2%）,hypertension（7.1%）,proteinuria（7.1%）,respectively. [Conclusions] Apatinib is active for the treatment of advanced refractory soft tissue sarcomas with a manageable tolerability profile.

关 键 词：阿帕替尼 软组织肉瘤 疗效 不良反应 

分 类 号：R738.6[医药卫生—肿瘤]